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Background – Clinical trials in irritable bowel syndrome (IBS) are associated with high placebo response rates. 
We aimed to identify the magnitude and the contributing factors to this placebo response rate in pharmacological 
trials in IBS.   
 
Methods – We conducted a systematic review and meta-analysis with a medical search on MEDLINE, EMBASE 
and the Cochrane Central Register of Controlled Trials between 01/04/1959 and 30/04/2020. We included all 
randomized controlled trials (RCTs) with a dichotomous outcome of response to therapy (in terms of global 
improvement or improvement in abdominal pain) in adult patients with IBS that compare an active 
pharmacotherapeutic agent with placebo. Exclusion criteria were trials reporting on treatment satisfaction as 
outcome or clinician-reported outcomes and a treatment duration of less than four weeks. The main outcome 
assessed was the identification of the magnitude of the pooled placebo response rate, for the following endpoints: 
global improvement responder, abdominal pain responder and the FDA endpoints. We extracted information 
from published reports and pooled proportions through meta-analysis with random effects. In addition, several 
variables were examined to investigate the moderating effect on the placebo response. The study was registered 
with PROSPERO, CRD42020170908. 
 
Findings – Of the 6863 publications identified, 73 RCTs were included in our analysis. The pooled placebo 
response rate was 27·3% (95% CI 24·3%-30·9%) using the global improvement-, 34·4% (95% CI 31·2%-
37·8%) using the abdominal pain- and 17·9% (95% CI 15·2%-21·0%) using the composite FDA endpoint 
responder definition, all with substantial heterogeneity between the trials. Studies published prior to 2006, 
conducted in Europe, with a parallel design, a run-in period of ≤ two weeks, a dosage schedule of ≥ three times a 
day, and a smaller sample size of the control group were significantly associated with a higher pooled placebo 
response rate.  
 
Interpretation – The pooled placebo response rate in pharmacological trials in IBS is 27·3% for the global 
improvement responder endpoint. Multiple moderators were associated with the pooled placebo response rate; 
we recommend future trials to apply a run-in period of at least two weeks and a daily dosage of one or two times 
a day with the purpose of minimizing the placebo response rate.  
 




Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction characterized by recurrent 
abdominal pain associated with defecation or a change in bowel habits.1,2 The estimated prevalence in a recent 
study is 4·6% in the Western world (according to the Rome IV criteria).3 IBS is not only associated with a 
significant impact on an individuals’ functioning and quality of life, but also with substantial costs to patients, 
healthcare systems and society.4,5 The treatment of IBS is commonly known to represent a clinical challenge, in 
part due to varying efficacy of different therapies.1,6 In order to improve therapeutic outcomes, furthermore in-
depth understanding of the mechanisms relevant to existing strategies is necessary, including the role of placebo 
in trials for IBS. In general, pharmacological therapies are considered efficacious if they are superior to placebo 
in clinical trials.2 The magnitude of the placebo response therefore has profound effects on the outcomes. 
Previous pharmacological trials in disorders of gut-brain interaction, including IBS, have shown that there is a 
significant proportion of patients that benefits from placebo intervention.7 The previous meta-analysis in the 
placebo response in IBS by Ford and Moayyedi (2010) showed a pooled placebo response rate of 37·5% (95% 
CI 34·4%-40·6%, with a wide range between 0% to 91·7%).8 Due to the high placebo response rate in IBS trials, 
the assay sensitivity (i.e., the ability of a trial to successfully differentiate between an effective and an ineffective 
treatment) is generally low.  
 
Placebo responses in IBS have received increasing attention over the years.9 The placebo effect has been 
identified as a phenomenon influenced by multiple factors of the psychosocial treatment context, including 
patient characteristics and doctor-patient communication, as well as the normal symptom fluctuation over time in 
many diseases. In the context of RCTs (randomized clinical trials) in IBS, study or trial characteristics, including 
trial duration and number of study visits, have been identified.10 In this respect, a number of systematic reviews 
in the past have attempted to identify specific moderators of the placebo response in IBS, but with conflicting 
results.8,11,12 An improved knowledge regarding moderators in clinical trials therefore remains warranted in order 
to minimize the magnitude of the placebo response in clinical trials by optimizing trial designs to increase the 
likelihood of demonstrating the effectiveness of pharmacological treatment.10 This is especially called for given 
the recent publication of the Rome IV (2016) guidance that generated substantial advances in several aspects of 
clinical trial design2, and publication of the European Medicines Agency (EMA)13 and the Food and Drug 
Administration (FDA)14 standards for responder definition in IBS clinical trials. As far as we know, the effects of 
these novel definitions and recommendations on the placebo response rate have not yet been studied, despite the 
fact that a large number of trials have been conducted since then.  
 
Therefore, we conducted a systematic review and meta-analysis with the aim to characterize the pooled placebo 
response rate in pharmacological RCTs of IBS and to identify the moderators, based on those previously 






This systematic review and meta-analysis was performed in accordance with the guidance provided by the 
Cochrane Handbook for Systematic Reviews of Interventions15 and the PRISMA guidelines16. The search was 
registered in PROSPERO, the International Prospective Register of Systematic Reviews (registration number: 
CRD42020170908).17  
 
Search strategy and selection criteria 
We conducted a search of the medical literature to identify potential studies using MEDLINE (April 1959 – 
April 2020), EMBASE (January 1974 – April 2020), and the Cochrane Central Register of Controlled Trials 
(April 1959 – April 2020). Eligible trials were RCTs that examined the effect of pharmacological therapies 
compared to a control arm with a placebo (as a pill/tablet/capsule). The participants of the study population had 
to be adult (18 year or older) with the diagnosis IBS (based on either symptom-based diagnostic criteria, i.e., 
Rome criteria, or a physicians’ assessment). A minimum treatment duration of four weeks in which active 
therapy was given was required (in line with recommendations for treatment trials for disorders of gut-brain 
interaction).2,13 Trials had to report a dichotomous outcome of response to therapy, in terms of global 
improvement or improvement in abdominal pain. The outcome had to be reported by the patient.2 The first 
period of cross-over RCTs was eligible for inclusion if the authors provided data prior to cross-over. We 
excluded trials with treatments other than pharmacological therapies (e.g. dietary interventions, food 
supplements or psychological therapies), reporting on treatment satisfaction as outcome18, duplicates or 
reanalysis of previously obtained trial data, and a publication type of the article other than a full-text article (e.g. 
conference abstract, due to incomplete data for our outcome assessment). There were no language restrictions. 
Corresponding authors of the studies were contacted if the full-text article was not available.   
 
The search was independently conducted by two investigators (T.B. and M.B.). A medical librarian was 
contacted for supervision of the search. Trials in IBS were identified using the following terms: irritable bowel 
syndrome (as medical subject heading and free-text term), irritable colon, IBS, spastic colon or spastic bowel (as 
free-text terms, combined using the set operator “OR”). These terms were then combined using the set operator 
“AND” with studies identified using the following terms: placebo or placebo effect (both as medical subject 
heading and free-text terms). Articles identified by the search were assessed and extracted by their abstract, 
independently by two investigators (T.B. and M.B.), according to the predefined eligibility criteria. 
Subsequently, all potentially relevant papers were obtained and evaluated independently by the two investigators 
in greater detail in order to assess eligibility. Disagreement between the investigators was resolved by discussion 
with a third investigator (D.K.).  
 
Data analysis 
The primary outcome assessed was the magnitude of the placebo response rate. For the primary outcome 
assessment, we distinguished between (i) a global improvement responder (i.e. patients reporting global 
improvement) after therapy with placebo, (ii) an abdominal pain responder (i.e. relief of abdominal pain) after 
therapy with placebo, and (iii) a responder according to the composite FDA endpoint after therapy with placebo 
(defined as: ≥30% abdominal pain reduction and increase ≥1 CSBM from baseline in the same week (IBS-C) or 
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a ≥50% reduction in the number of days per week with at least one stool that has a consistency of type six or 
seven compared with baseline (IBS-D) for at least 50% of the weeks of treatment)14. The composite FDA 
endpoint was also assessed separately for pain response and ‘bowel symptom response’ (i.e. the change in stool 
frequency or consistency). The secondary outcome assessed was the effect of moderators (various trial and 
patient characteristics, based on moderators identified from previous systematic reviews, see below) on the 
pooled placebo response rate, according to the combined responder definition (i.e. the primary endpoint of each 
specific trial, either global improvement, improvement in abdominal pain or the FDA endpoint, as the trials were 
generally powered for their specific primary endpoints). 
For all included trials, data were extracted independently by two investigators (T.B. and M.B.) into a Microsoft 
Excel spreadsheet as dichotomous outcomes (responder versus non-responder). The following data were also 
extracted for each trial, where available: year of publication, geographical setting, trial setting (single versus 
multicenter and primary versus secondary/tertiary care), study design (parallel versus cross-over), run-in phase 
(duration and use of placebo), study size, randomization ratio, mean age, sex, criteria used to define IBS, subtype 
of IBS, mean duration of diagnosis/symptoms, baseline abdominal pain, type of active therapy, duration of 
therapy, dosing schedule/escalating dose, number of face-to-face visits, proportion of side effects, and dropouts 
in the control group, therapeutic response in the active treatment group. Corresponding authors of studies were 
contacted to provide additional information on individual studies where required. Foreign language papers were 
translated where necessary. Data were extracted as intention-to-treat analyses, with dropouts assumed to be 
treatment failures, wherever trial reporting allowed this, in accordance with the guidance provided by the 
Cochrane Handbook for Systematic Reviews of Interventions15.  
 
The Cochrane Risk of Bias Tool was used to access the risk of bias at the individual study level.19 This was 
performed by two investigators independently (D.K. and M.B.). Disagreements were resolved by discussion. 
Bias was assessed as a judgement (low, unclear or high risk of bias) for six domains of bias (sequence 
generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting and other 
sources of bias). Criteria for the judgement of high risk of bias were either 1 domain with high risk of bias or 4 
domains with unclear risk of bias. Studies at high risk of bias were then excluded from further assessment.   
 
Data were stored and analyzed using R version 4.0.1 (R Core Team [2020]. R: A language and environment for 
statistical computing. R Foundation for Statistical Computing, Vienna, Austria). Data were pooled from the 
placebo arms of the clinical trials using a random-effects model based on logit transformation, allowing for any 
heterogeneity between trials. Separate analyses were run to evaluate the pooled placebo across all studies for the 
global improvement responder, abdominal pain responder, combined endpoint (primary outcome - either global 
improvement or abdominal pain responder - of the specific study), composite FDA endpoint and the FDA 
endpoint abdominal pain responder, with a 95% confidence interval (CI). Data were presented in forest plots and 
funnel plots were included for detecting publication bias. Some variables (i.e. IBS-D and IBS-C) were examined 
separately in a subgroup analysis, with a 95% confidence interval (CI). Post hoc, previous analyses were also 
conducted for the intervention arms of the clinical trials. In order to obtain the therapeutic gain, the difference 
between the intervention response rate and placebo response rate was calculated separately for each trial and 
subsequently pooled using a random-effects model. 
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Moderators were extracted as beforementioned (predefined). Each moderator was examined in a separate meta-
regression model rather than in a combined model to avoid overfitting of data and listwise deletion (i.e. some 
moderators are measured in one study but not in another study). Results were expressed in odds ratios with a 
95% confidence interval (CI). Heterogeneity was evaluated using I2-statistics (interpreted as low heterogeneity 
(<25%), moderate heterogeneity (25%-50%) and high heterogeneity (>50%)) and homogeneity was evaluated 
using the Q-statistics (with P < 0·10 considered statistically significant).20 A p-value of ≤ 0·05 was considered 
statistically significant. 
 
Role of the funding source 
There was no funding received for this study. All authors have confirmed they had full access to all the data in 






The search strategy (Figure 1.) generated 6863 citations, 279 of which appeared to be relevant based on 
screening title and/or abstract and were retrieved for further assessment. Of these, 198 trials were excluded for 
various reasons, leaving 81 eligible trials that met our inclusion criteria. Each study’s risk of bias was assessed, 
after which 1121-31 additional trials were excluded due to high risk for bias. Eventually, 73 RCTs (described in 70 
articles32-101) were included in the meta-analysis.  Detailed characteristics of individual trials are provided in the 
Supplementary (see Supplementary page 2 and 4). The bias assessment of all trials is reported in the 
Supplementary (see Supplementary page 5). The risk of bias was low for most of the included trials (58 of the 70 
trials). However, selection bias is unclear for several included studies because the allocation concealment may be 
compromised by treatment-specific side effects. In addition, in a number of trials a high drop-out ratio (1 (20%) 
of 5 patients) was reported or the sample size calculation was unclear. 
 
Figure 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analysis Analysis) flow 
diagram of trials identified, excluded and included in the meta-analysis 
 
Sixty trials provided data for the outcome assessment of proportion of patients who were global improvement 
responders (Figure 2a. and 2b., Table 1.). The placebo response rate ranged from 4·7% to 68·6%, with an overall 
pooled placebo response rate of 27·3% (95% CI 24·3%-30·9%), with substantial heterogeneity between the trials 
(I2 90·73%). The pooled intervention response rate for this endpoint was 42·5% (95% CI 38·7%-46·4%), with 
substantial heterogeneity between the trials (I2 95·37%), resulting in a therapeutic gain of 13·8% (95% CI 
11·4%-16·1%). Out of these sixty trials, twenty trials provided data from the IBS with diarrhea subtype with a 
pooled placebo response rate of 27·2% (95% CI 22·4%-32·7%) and twenty-two trials provided data from the 
IBS with constipation subtype with a pooled placebo response rate of 23·3% (95% CI 19·3%-27·9%).  
Forty-eight trials provided data for the outcome assessment of proportion of patients who were abdominal pain 
responders (Figure 2c. and 2d., Table 1.). The placebo response rate ranged from 13·3% to 63·7%, with an 
overall pooled placebo response rate of 34·4% (95% CI 31·2%-37·8%), with substantial heterogeneity between 
the trials (I2 89·37%). The pooled intervention response rate for this endpoint was 46·8% (95% CI 43·5%-
50·2%), with substantial heterogeneity between the trials (I2 93·53%), resulting in a therapeutic gain of 12·0% 
(95% CI 9·3%-14·7%). Out of these forty-eight trials, twenty-three trials provided data from the IBS with 
diarrhea subtype with a pooled placebo response rate of 33·6% (95% CI 30·1%-37·4%) and thirteen trials 
provided data from the IBS with constipation subtype with a pooled placebo response rate of 31·5% (95% CI 
25·1%-38·7%).  
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Figure 2a. Forest plot of proportion of placebo responders, with endpoint global improvement responder 
(total of articles with this endpoint: n = 60).  
  
Figure 2b. Funnel plot of proportion of placebo responders, with endpoint global improvement responder 












Figure 2c. Forest plot of proportion of placebo responders, with endpoint abdominal pain responder (total 




Figure 2d. Funnel plot of proportion of placebo responders, with endpoint abdominal pain responder 



















Twenty trials provided data for the outcome assessment of proportion of patients who were composite FDA 
endpoint responders (Figure 3a. and 3b., Table 1.). The overall pooled placebo response rate was 17·9% (95% CI 
15·2%-21·0%), with substantial heterogeneity between the trials (I2 82·84%). The pooled intervention response 
rate for this endpoint was 29·1% (95% CI 26·0%-32·4%), with substantial heterogeneity between the trials (I2 
88·55%), resulting in a therapeutic gain of 11·7% (95% CI 9·5%-13·9%). Out of these twenty trials, nine trials 
provided data from the IBS with diarrhea subtype with a pooled placebo response rate of 21·1% (95% CI 16·6%-
26·4%) and ten trials provided data from the IBS with constipation subtype with a pooled placebo response rate 
of 15·7% (95% CI 12·6%-19·4%).  
Nineteen trials provided data for the outcome assessment of proportion of patients who were FDA endpoint 
abdominal pain responders (Table 1.). The overall pooled placebo response rate was 35·1% (95% CI 30·6%-
39·9%), with substantial heterogeneity between the trials (I2 89·06%). The pooled intervention response rate on 
this endpoint was 45·7% (95% CI 41·2%-50·2%), with substantial heterogeneity between the trials (I2 92·42%), 
resulting in a therapeutic gain of 10·9% (95% CI 6·4%-15·5%). Out of these nineteen trials, eight trials provided 
data from the IBS with diarrhea subtype with a pooled placebo response rate of 37·0% (95% CI 29·5%-45·1%) 
and nine trials provided data from the IBS with constipation subtype with a pooled placebo response rate of 
34·6% (95% CI 28·4-41·5%).  
Nineteen trials provided data for the outcome assessment of proportion of patients who were FDA endpoint 
bowel symptom responders (Table 1.). The overall pooled placebo response rate was 28·3% (95% CI 23·4%-
33·8%), with substantial heterogeneity between the trials (I2 92·73%). The pooled intervention response rate on 
this endpoint was 42·6% (95% CI 37·4%-47·9%), with substantial heterogeneity between the trials (I2 95·04%), 
resulting in a therapeutic gain of 13·3% (95% CI 10·2%-16·5%). Out of these nineteen trials, nine trials provided 
data from the IBS with diarrhea subtype with a pooled placebo response rate of 29·2% (95% CI 20·%-39·3%) 
and ten trials provided data from the IBS with constipation subtype with a pooled placebo response rate of 
27·4% (95% CI 21·6%-34·1%). 
 
Figure 3a. Forest plot of proportion of placebo responders, with endpoint composite FDA endpoint 
responder (total of articles with this endpoint: n = 20) 
  
 11 
Figure 3b. Funnel plot of proportion of placebo responders, with endpoint composite FDA endpoint 
responder (total of articles with this endpoint: n = 20) 
 
 
There were multiple moderators associated with the magnitude of the placebo response rate as defined by the 
combined endpoint (Table 2.). There was a significant effect of the year of publication on the placebo response 
rate. Specifically, the trials published before 2006 (i.e. corresponding to the publication of the Rome III 
criteria2,which was used as a surrogate marker of the process of increased scientific rigor of clinical trial conduct 
and quality of reporting) had a larger pooled placebo response rate compared with trials published in or after 
2006 (37·2% vs. 28·9% respectively, p=0·032). The trial location also had a significant effect on the place 
response rate. Trials conducted in Europe had a significant larger pooled placebo response rate compared with 
trials conducted in the United States (38·9% vs. 25·7% respectively, p=0·0032) and a non-significant larger 
pooled placebo response rate compared with trials conducted in Asia (38·9% vs. 30·3% respectively, p=0·068). 
Some active pharmacological agents were significantly related to the placebo response rate. Further specified; in 
active agents used for IBS-D, trials with 5-HT3 antagonists had a significant larger pooled placebo response rate 
compared with trials with opioid receptor agonists as active agent (32·3% vs. 16·2% respectively, p=<0·0001). 
In active agents used for IBS-C, trials with 5-HT4 antagonists had a significant larger pooled placebo response 
rate compared with trials with secretagogues as active agent (36·1% vs. 20·8% respectively, p=0·0030).  
The trial setting (single versus multicenter and primary versus secondary/tertiary care) was not significantly 
related to the placebo response rate. By contrast, there was a significant effect of the study design on the placebo 
response rate. Cross-over studies had a significant lower pooled placebo response rate compared with parallel-
studies (18·4% vs. 32·8% respectively, p=0·0081). There was a positive association between the duration of the 
run-in period and the placebo response. For trials with a run-in period of 2 weeks or less, the placebo response 
rate was significantly higher than trials with a run-in period of more than 2 weeks (34·6% vs. 19·4% 
respectively, p=0·0001). However, there was no significant association between placebo run-in versus no 
treatment in the run-in period (p=0·10). There was a significant effect of the dosage schedule on the placebo 
response rate. Trials with a dosage schedule of once or twice a day had a significant lower pooled placebo 
 12 
response rate compared with trials with a dosage schedule of three times a day or more (29·4% vs. 40·1% 
respectively, p=0·025). The use of an escalating dose, mean age, the duration of IBS symptoms/time since 
diagnosis, the proportion of patients assigned to placebo, and the level of bias were not significantly related to 
the placebo response rate. 
 
Finally, we performed the meta-regression analysis of numeric variables for the combined responder definition 
(Table 3.). We found a significant association between the size of the placebo group and the placebo response 
rate (p=0·016), indicating that larger trials were more likely to have a lower placebo response. There was no 
significant association when comparing the size of the placebo group with the therapeutic gain (see 
Supplementary page 6). Also, the duration of therapy (against the proportion of placebo responders and the 
therapeutic gain), the study visits, the proportion of males, the baseline abdominal pain, and proportion of side 
effects and dropouts were not associated with the placebo response rate. We performed the same meta-regression 
analysis for the FDA endpoint responder outcome (Table 3.) (see Supplementary page 6). However, there was no 
significant relationship between any of the abovementioned variables.  
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Discussion  
In this meta-analysis describing 73 IBS RCT’s, the magnitude of the placebo response rate was 27·3% using the 
global improvement responder definition, 34·4% using the abdominal pain responder definition, 17·9% using the 
FDA endpoint composite responder definition. When subdividing the FDA composite endpoint, the pooled 
placebo response rate was 35·1% using the FDA endpoint abdominal pain responder definition and 28·3% using 
the FDA endpoint bowel symptom responder definition. Studies published prior to 2006, with a parallel design, a 
run-in period of two weeks or less, a dosage schedule of three times or more a day, studies conducted in Europe, 
and a smaller study size in the control group were significantly associated with a higher placebo response rate.  
 
This meta-analysis was prompted by the fact that the recent introduction of the novel trial endpoints and 
diagnostic criteria have changed the landscape for IBS trials. A number of findings of our current analysis are in 
line with the most recent meta-analysis on the subject8, i.e. the higher placebo response in trials conducted in 
Europe and in trials that used a higher daily dosing schedule. Other similarities were found in the moderators that 
had no or only modest effects on the pooled placebo response rate, namely the trial setting and patients’ 
predominant stool pattern. In addition, the finding that the pooled placebo response rates were highest in trials 
that used antispasmodics as active agent, not statistically significant though when compared with peppermint oil 
as active agent, is another resemblance. Contrary to our study, Ford and Moayyedi found no significant effect of 
the year of publication on the placebo response rate, which could be related to the 10-year time gap between the 
two meta-analyses.  
 
The pooled placebo response rates in this meta-analysis are lower than reported before, with pooled placebo 
response rates of 36·0% (95% CI not mentioned)11, 37·5% (95% CI 34·4%-40·6%)8 and 40·2% (95% CI 35·9%-
44·4%)12. This could be explained by the number of trials included in this meta-analysis, the distinction between 
different responder definitions (in particular the novel FDA definitions) and the inclusion of a considerable 
number of recent trials. Our results have shown that more recent studies have a significantly lower pooled 
placebo response rate. Interestingly, this trend appears to be at odds with the increase of the pooled placebo 
response rates observed in other disorders, such as depression, schizophrenia and neuropathic pain 102,103. The 
fact that more recent clinical trials in IBS had larger sample sizes10 and the modifications in study design based 
on new guidelines, including the Rome III and later Rome IV criteria2, EMA13 and FDA14 recommendations, 
have favored the development towards lower placebo response rates in IBS. As a result, we consider it futile to 
compare studies before 2006 with studies performed in 2006 or later. 
 
For the following variables, our results on the association between the moderators and the placebo response rates 
are in line with previous studies: the significant effect of studies conducted in Europe8,104, a parallel design,103,105 
and a dosage schedule of three times or more a day8,11; and no significant effect of sex10,106,107, age,106,107 and trial 
setting8,11,12 on the placebo response rate. For the study duration8,10,11,108, disease severity, and disease 
duration102,103,106,109,110 , previous findings have shown incongruent results, which could be related to different 
selection criteria. Our results did not show a significant association between these moderators and the pooled 
placebo response rate. Therefore, together these findings do not support the notion that there may be placebo 
“responders” or “non-responders” based on individual characteristics (age, sex) – which would mean that trials 
 14 
should select participants based on criteria to reduce placebo responses. With the present data, it becomes clearer 
that it is not the individual but rather the trial design and trial characteristics that are important to modify. 
 
We have shown that longer run-in phases are significantly associated with a lower pooled placebo response rate, 
in line with previous studies.11,12 However, the translation to the daily practice becomes more difficult as the run-
in period is extended. Therefore, we recommend future trials to apply a run-in phase of at least two weeks to 
reduce the placebo response rate. The use of a placebo run-in is questionable.111 The purpose of a placebo run-in 
is eliminating patients who respond to the placebo during run-in and thereby decreasing placebo response rates 
following randomization in the active treatment phase. It is interesting to note that, in line with studies in other 
disorders112-114, our results demonstrated no benefit of a placebo run-in on the placebo response rate. In addition, 
a placebo run-in creates a selection bias and a discrepancy between the trial population and the clinical patient 
population.106,111,115 Because of the risk of underestimating the overall effect size2 and the lack of evidence of the 
placebo run-in in decreasing the placebo response rate, there appears to be insufficient substantiation for the use 
of a placebo run-in in future trials. However, it is important to note that these results are based only on the three 
trials with a placebo run-in. Therefore, further research is needed to establish the exact effects of placebo run-ins 
on overall placebo response prior to establishing a firm recommendation. 
 
In May 2012, the FDA14 published interim endpoints for IBS trials. Although harmonization of trial design in 
IBS was warranted, it has been a matter of debate whether the quantification of only two, albeit cardinal, IBS 
symptoms, namely abdominal pain and disordered defecation, is able to integrate the multidimensional aspect of 
the IBS symptoms to a sufficient degree116, and it is has been suggested that less robust endpoints might be 
superior or at least equal in clinical decision-making.117 Our results (Table 1. and Figure 4.) demonstrated an 
approximately 10% lower placebo response rate for the composite FDA endpoint in comparison with the 
historically commonly applied improvement responder endpoint. However, the intervention response rate has a 
similar trend, with an estimated 13% reduction, resulting in a therapeutic gain nearly the same (13·8% versus 
11·7%) as before the introduction of the FDA endpoints. Identical results were observed for the abdominal pain 
responder endpoint. This would imply no apparent advantage of the FDA endpoint in demonstrating the efficacy 
of the active therapy. Conversely, the FDA endpoint seems less dependent on specific moderators, such as the 
sample size of the placebo group. At this point, we believe that the introduction of the FDA endpoint represents 
an excellent step in the right direction to uniformization in IBS trials, but further investigation of the 
performance of this endpoint is required. 
 
Previous studies have not been able to demonstrate an association between the sample size of the placebo group 
and the placebo response rate.8,11,12 Our findings did show such an association, which was significant, when 
assessing the combined responder endpoint. Interestingly, this association was not found for the FDA composite 
endpoint, which suggests that this endpoint is less sensitive to the sample size. On the other hand, no association 
was found between sample size and therapeutic gain for any of the endpoints. 
 
Figure 4. L’Abbe plot of the response rate in the intervention group against the response rate in the 




Interestingly, we found a higher pooled placebo response rate with the abdominal pain responder endpoints 
compared to the global improvement responder endpoints and the symptom bowel responder endpoint, which is 
in line with previous findings11. We speculate that this might be due to the fact that it is easier and more 
accessible for patients to delineate an improvement specifically for abdominal pain, rather than for a much 
broader symptom complex with different elements, as in global improvement. In addition, it could also be the 
case that the symptom of abdominal pain is more modifiable by placebo mechanisms (cognitive factors), is more 
easily remembered, or that it is most in the center of attention for the patient due to its salience, especially if the 
treatment information refers to improvement specifically for this symptom. Finally, the 30% improvement in 
abdominal pain, which defines the pain responder according to the FDA endpoint, may be substantial hurdle 
allowing a large placebo response.115 Indeed, in some studies exploring a higher pain improvement threshold 
generated a bigger margin over placebo.86,97 
Of note is further that, for the purposes of the current analyses, we did not focus on the symptoms of bloating 
and abdominal discomfort because of the widespread nature and the less well-defined character of these 
symptoms.118 Indeed, abdominal discomfort has also been removed from the Rome IV criteria. In addition, an 
improvement in the symptom of bloating or abdominal discomfort, subsequently associated with a higher pooled 
placebo response, is neither sensitive nor specific for IBS alone, even in pre-Rome IV trials, resulting in an 
unjustified higher placebo response. 
 
As for moderators of the placebo response, treatment expectations, denominated in behavioral, psychobiological, 
and contextual factors (e.g. conditioning, patient-clinician relationship), appear to be relevant.10,13,119 A higher 
pooled placebo response rate is associated with an unbalanced randomization in multiple neurological and 
psychiatric conditions10,106 and a higher number of study visits.11,106 However, our results did not show this 
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association. An explanation may be that most trials did not report (or measure) these potential moderators 
towards the treatment expectation. Although this may be difficult to objectify, in order to make an adequate 
assessment about these moderators affecting treatment expectations, we advocate for more accurate and detailed 
reporting of these in future trials.10 In addition, assessing possible unblinding can also provide insight in 
treatment expectation. This can be accomplished, in line with FDA recommendations120, by including a single 
item at the end of the trial to ask patients to identify the clinical trial arm in which they believe they participated. 
 
Previous studies have shown that patients are more likely to report symptom improvement if they subjectively 
perceive an effect of the drug (including side effects), while patients without any side effects may believe the 
therapy is ineffective and for this reason may drop out.2,10,121,122 We found no such association in our results. 
However, these phenomena are complex and may include a multitude of underlying mechanisms including the 
content and mode of delivery of information during informed consent, driving a delicate balance between 
placebo and nocebo effects, hereby modifying treatment expectations in both directions, positive and negative.106 
This can also have profound effects on symptom experience, patient expectations about the active 
pharmacological therapy used and reporting in the context of clinical trials. The complexity of these phenomena 
does not allow to draw firm conclusions on the basis of the current analyses.121,122 
 
The strength of this study includes the magnitude and detailed assessment of various moderators influencing the 
pooled placebo response rate. Furthermore, IBS-D and IBS-C were included as a sub-analysis rather than a 
separate primary analyses given the intent of the study. It is important to note, however, that regulatory agencies 
do not currently recognize "IBS" as a separate identity. Instead, drugs can only be evaluated for either IBS-D or 
IBS-C and this calls for future scrutiny of the IBS definitions currently used by regulatory agencies. 
There are, however, some limitations to be noted. First, 12 of the 80 trials were at unclear risk of bias, which 
may have influenced results on the pooled placebo response rate. Considering the fact that we did not find an 
effect of the level of bias on the placebo response rate, it is more likely that these deficiencies objectify lack of 
reporting of design details assessed in The Cochrane Risk of Bias Tool, rather than true design defects. Second, 
variability in subject behavior during trial period (diet, exercise, stress) and clinical evolution of the disorder 
during studies could not be extracted from the trials but may influence the placebo response. Thirdly, our results 
rely on the reporting of the included trials and as mentioned above, some moderators, particularly in older trials, 
have been inadequately reported. There is substantial heterogeneity in trial design, endpoints and reporting, 
making pooling of results for purposes of a meta-analysis inherently difficult. Therefore, for the primary 
outcome of these analyses, we analyzed different study endpoints separately. As for the moderator analysis, we 
chose to perform analysis according to the primary outcomes for which the particular trial was powered for, 
allowing some correction for differences in study design.  
 
In conclusion, the magnitude of the pooled placebo response rate in pharmacological trials in IBS is 27·3% for 
the global improvement responder endpoint. After the introduction of the interim composite FDA endpoint, the 
pooled placebo response showed a decline to 17·9%, but the therapeutic gain remained unaltered. On the other 
hand, it tributes to the harmonization in IBS trials and the introduction of the FDA endpoint, as this seems less 
sensitive to the sample size of the placebo group. Multiple moderators were associated with a higher pooled 
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placebo response rate. Based on the current findings, we suggest future pharmacological trials in IBS, with the 
purpose of minimizing the pooled placebo response rate, to apply a run-in period of at least two weeks 
(preferably without a placebo-therapy pending further research on this topic), and a daily dosage of one or two 
times a day. Sample size calculations should consider a therapeutic gain of 11-15%, when using a dichotomous 
outcome, depending on the outcome parameter chosen. In addition, an adequate assessment and reporting in the 
future is needed on variables associated with treatment expectancies (both positive and negative) prior to as well 
as during treatment.  
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Research in context  
Evidence before this study 
It is well-established that trials in Irritable Bowel Syndrome (IBS) are characterized by a high placebo response 
(the previous meta-analysis (2010) showed a pooled placebo response rate of 37·5%), which largely influences 
the success of these trials. As for the factors affecting placebo response in clinical trials, previous systematic 
reviews have shown conflicting results. In addition, all these analyses predate the recent FDA/EMA responder 
definition. We conducted a systematic review and meta-analysis to identify the pooled placebo response rate in 
pharmacological randomized controlled trials (RCTs) in adult patients with IBS in order to better understand the 
factors affecting the placebo response rate and to control them. We searched MEDLINE, EMBASE and the 
Cochrane Central Register of Controlled Trials between the 1st of April 1959 and 30th April 2020 using search 
terms for IBS (irritable bowel syndrome, IBS, irritable colon, spastic colon and spastic bowel) and placebo 
response (placebo and placebo effect) with no language restrictions. Only studies that reported a dichotomous 
outcome of response to therapy with a minimal therapy duration of four weeks were included.  
 
Added value of this study  
This meta-analysis of 73 RCTs highlights different moderators that are associated with a higher pooled placebo 
response rate in pharmacological trials in IBS. In addition, we found a decrease in the pooled placebo response 
rate after the introduction of the composite FDA endpoint, but the therapeutic gain remained unaltered. These 
findings fill an important knowledge gap on the subject and can therefore represents a contribution to the field in 
optimizing trial design in IBS, not only for clinical gastroenterologist but also for the pharmaceutical industry.  
 
Implications of all the available evidence  
Based on the findings in this meta-analysis, we suggest future pharmacological trials in IBS, with the purpose of 
minimizing the pooled placebo response rate, to apply a run-in period of at least two weeks (preferably without a 
placebo-therapy pending further research on this topic), and a daily dosage of one or two times a day. There is a 
reporting (and assessment) gap in factors affecting patients’ treatment expectancies, causing an inadequate 
assessment of the influence of these factors on the pooled placebo response rate. An adequate assessment and 
reporting of these factors in the future is needed. 
Despite the unaltered therapeutic gain after the introduction of the FDA endpoint, advantages of the FDA 
endpoints are the contribution to the harmonization in IBS trials and the FDA endpoint seems less sensitive to 
the sample size of the placebo group. At this point, we believe that the introduction of the FDA endpoint 
represents an excellent step in the right direction to uniformization in IBS trials, but further investigation of the 
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